Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab and Lenvatinib in Advanced Solid Tumors
NCT05024214Phase 2Recruiting
- Sponsor
- 3D Medicines Inc.
- Start
- Nov 2021
- Primary completion
- Dec 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in solid tumor, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), sponsored by 3D Medicines Inc.. Started Nov 2021; status: recruiting.
02
Drugs
envafolimab
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05024214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024214.